Synlogic

Applying synthetic biology to probiotics to develop novel living medicines

Synlogic is developing a novel class of living Synthetic Biotic medicines based on its proprietary drug development platform. The company’s initial pipeline includes potential first-in-class treatments for orphan genetic diseases such as urea cycle disorders (UCD) and phenylketonuria (PKU). In addition, the company intends to leverage the potential of its platform to create additional potential first-in-class therapies for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer.

Status

Reverse Merger in 2018 (NASDAQ: SYBX)

Year of Investment

2018

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Cambridge, Massachusetts